ESR2 and cancer: Although treatment with the selective ERβ agonist DPN appeared to counteract this effect when only endothelial cells were stimulated with E2 during differentiation (E2+DPN), this was not the case when both cancer and endothelial cells were pretreated with E2 (E2+E2+DPN).